On May 22, 2024, the fourth session of thesecond council of the Innovation Alliance was held at the Longemont Hotel in Shanghai. The event was attended by members and invited guests frominstitutions such as the Clinical Pharmacy Innovation Institute of Shanghai Jiao Tong University School of Medicine, the Innovation Promotion Branch of the China Pharmaceutical Commerce Association, the Shanghai Smart AlliancePharmaceutical Service Innovation Promotion Center, the Shanghai Yangtze RiverDelta Smart Medicine Technology Innovation Promotion Center, Abbott (China), Sinopharm Group, Shanghai Pharma, CR Pharma ,GY Health, Iron-Tech, Intmedic, BD (China), G-Healthy, Yuanxin Technology, Realcan, Grandall Law Firm, Weibond, Anzhizhuo, Yao123.cn, Vansys Health, Loccioni, HaoyiCulture, and related hospitals, either in person or online. Over a thousandpeople watched the live-streamed images of the meeting.
The meeting was chaired by RotatingChairman Cao Weirong, with an opening speech by Rotating Chairman Zhang Jian.He emphasized the importance of the Innovation Alliance's public welfare,innovation, compliance, and operability under the current anti-corruptionlandscape in the pharmaceutical industry. He expressed hope that the Alliancewould focus on high-quality development in the medical and pharmaceuticalindustries, promote academic exchanges, advance the implementation of projectsby the innovation committees, and establish service norms and qualitystandards. These efforts aim to achieve innovative breakthroughs in the GreaterBay Area and Beijing-Tianjin-Hebei region, building on the foundation in theYangtze River Delta.
Rotating Chairman Cao Weirong then reviewedand summarized the work of the Innovation Alliance and proposed the next steps.
The ceremony for appointing members to thespecialized committees of the Innovation Alliance was hosted by Senior ChairmanZhang Xiaomin. Rotating Chairmen Geng Yili, Zhang Jian, and Fu Xudong awardedcertificates of appointment and signed related pilot project cooperationmemoranda with Liu Gang, the Executive Chairman of the "Smart AccessInnovation Committee," Ms. Jia Zaiyi, the Chairman of the "RareDisease AI Diagnosis and Treatment Committee," and Luo Dongtao, theExecutive Chairman of the "Multilevel Healthcare Security InnovationCommittee."
Following this, Executive Chairman Liu Gangshared insights on "Smart Access Innovation Practices," and Mr. WenKai, Marketing Director of Amelon Technology Co., Ltd., introduced thecompany's innovative projects.
In the brainstorming session, jointly hosted by Senior Chairman Zhang Xiaomin and Rotating Chairman Xu Qiding, the participating representatives reached a consensus on the following goals:
- Ad here to a public welfare orientation, providing compliant and operational innovative solutions for all member units of the Innovation Alliance.
- Promote the implementation of public welfare innovation projects by the "Smart Access Innovation Committee," "Rare Disease AI Diagnosis and Treatment Committee," and "Multilevel Healthcare Security Innovation Committee."
- Advance the establishment of innovation centers in the Greater Bay Area and Beijing-Tianjin-Hebei region, expanding the national influence of the Innovation Alliance's public welfare initiatives.
Finally, Senior Chairman Li Dongjiu delivered an excellent summary of this council session.
